SAIF Invests In China’s Pharmaceutical Industry
This article was originally published in PharmAsia News
Executive Summary
ShenZhen Hybio Engineering has received an initial injection of $15 million venture capital from SAIF Partners and Shenzhen Capital Group. As a veteran in peptide R&D and marketing, Hybio enjoys the biggest peptide drug market share in China; it recently passed FDA's on-site audit in February 2007. The company revealed that the fund will be used in R&D for peptide drugs as well as in opening up international markets. Hybio represents SAIF's first investment in China's pharmaceutical industry and the private equity firm is optimistic of the industry's rapid growth opportunities arising from China's health care reform. It is currently in discussion with a Shanghai biomedical reagent producer. (Click here for more - Chinese Language)
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.